Dermal Cell News Volume 8.07 | Mar 7 2022

    0
    40







    2022-03-07 | DCN 8.07


    Dermal Cell News by STEMCELL Technologies
    Vol. 8.07 – 7 March, 2022
    TOP STORY

    ΔNp63-Senataxin Circuit Controls Keratinocyte Differentiation by Promoting the Transcriptional Termination of Epidermal Genes

    Investigators elucidated a mechanism whereby ΔNp63 efficiently sustained the expression of epidermal differentiation genes.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract
    Subscribe to the Stem Cell Podcast YouTube Channel
    PUBLICATIONSRanked by the impact factor of the journal

    Characterization of a Melanocyte Progenitor Population in Human Interfollicular Epidermis

    Researchers distinguished between three distinct types of melanocytes in human interfollicular epidermis: cKit+CD90, cKit+CD90+, and cKitCD90+.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Dried Human Cultured Epidermis Accelerates Wound Healing in Diabetic Mouse Skin Defect Wounds

    Scientists prepared dried cultured epidermis (CE) and investigated its morphological and physical properties and wound-healing effects and compared them with those of cryopreserved CE.
    [Scientific Reports]

    Full Article

    Adaptive Translational Reprogramming of Metabolism Limits the Response to Targeted Therapy in BRAFV600 Melanoma

    Investigators examined how targeted therapy reprogrammed metabolism in BRAF-mutant melanoma cells using a genome-wide RNA interference screen and global gene expression profiling.
    [Nature Communications]

    Full Article

    Novel Treatment Strategy for NRAS-Mutated Melanoma through a Selective Inhibitor of CD147/VEGFR-2 Interaction

    Researchers showed that CD147i, a specific inhibitor of CD147/VEGFR-2 interaction, represented a potential therapeutic strategy for NRASmut melanoma cells.
    [Oncogene]

    Abstract

    Long Noncoding RNA LINC01435 Impedes Diabetic Wound Healing by Facilitating YY1-Mediated HDAC8 Expression

    Scientists demonstrated that treatment with exosomes from high glucose-pretreated immortalized human epidermal cells could delay the wound healing process in diabetic mice.
    [iScience]

    AbstractFull ArticleGraphical Abstract

    Antagonism of the Transient Receptor Potential Melastatin-2 Channel Leads to Targeted Antitumor Effects in Primary Human Malignant Melanoma Cells

    Researchers determined the effects of antagonism of the transient receptor potential melastatin‑2 ion channel in primary human malignant melanoma cells.
    [International Journal of Oncology]

    Abstract

    High-Content Screening Pipeline for Natural Products Targeting Oncogenic Signaling in Melanoma

    An in-house library of 2576 plant extracts was screened on two melanoma cell lines with different oncogenic mutations leading to pathological ERK/AKT activity.
    [Journal of Natural Products]

    AbstractGraphical Abstract

    LncRNA XIST Engages in Psoriasis via Sponging MiR-338-5p to Regulate Keratinocyte Proliferation and Inflammation

    Scientists investigated the role and regulatory relationship between long noncoding RNA (lncRNA) XIST and miR-338-5p in psoriatic patients and cell models.
    [Skin Pharmacology and Physiology]

    Abstract
    Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart
    REVIEWS

    Beyond the Code: Noncoding RNAs in Skin Wound Healing

    The authors discuss current knowledge about the functional roles of noncoding elements in skin wound healing, focusing on in vivo evidence from studies of human wound samples and animal wound models.
    [Cold Spring Harbor Perspectives in Biology]

    Abstract

    Circulating MicroRNA Biomarkers in Melanoma and Non-Melanoma Skin Cancer

    Investigators summarize the state of the art on circulating microRNAs detectable in skin cancer patients including all the studies that performed microRNA identification and quantification in the circulation using appropriate sample size and statistics and provide detailed methodology.
    [Expert Review of Molecular Diagnostics]

    Abstract
    INDUSTRY AND POLICY NEWS

    Evaxion Biotech Completes Recruitment for Phase I/IIa Clinical Trial for EVX-02

    Evaxion Biotech A/S finalized recruitment for Phase I/IIa clinical trial of EVX-02 in adjuvant melanoma patients.
    [Evaxion Biotech A/S]

    Press Release

    Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase III KEYNOTE-716 Trial

    Merck announced that the Phase III KEYNOTE-716 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resected stage IIB and IIC melanoma met its key secondary endpoint of DMFS at a pre-specified interim analysis.
    [Merck & Co., Inc.]

    Press Release
    FEATURED EVENT

    13th Online Dutch Stem Cell Meeting

    April 16, 2022
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – Skin Barrier Function

    Technical University of Denmark – Lyngby, Denmark

    Research Assistant – Stem Cells and Regenerative Medicine

    King’s College London – London, England, United Kingdom

    Assistant Professor – Skin Immunology

    Lee Kong Chian School of Medicine – Singapore, Singapore

    Postdoctoral Research Associate – Skin Equivalents and Skin Cell Biology

    Durham University – Durham, England, United Kingdom

    Postdoctoral Fellow – Mammalian Skin Regeneration

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Dermal Cell News Twitter